ATE500236T1 - Mit lanthionin verwandte verbindungen zur behandlung entzündlicher krankheiten - Google Patents

Mit lanthionin verwandte verbindungen zur behandlung entzündlicher krankheiten

Info

Publication number
ATE500236T1
ATE500236T1 AT07710015T AT07710015T ATE500236T1 AT E500236 T1 ATE500236 T1 AT E500236T1 AT 07710015 T AT07710015 T AT 07710015T AT 07710015 T AT07710015 T AT 07710015T AT E500236 T1 ATE500236 T1 AT E500236T1
Authority
AT
Austria
Prior art keywords
lanthionine
compounds
derivatives
treatment
provides
Prior art date
Application number
AT07710015T
Other languages
English (en)
Inventor
Kenneth Hensley
Original Assignee
Oklahoma Med Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found filed Critical Oklahoma Med Res Found
Application granted granted Critical
Publication of ATE500236T1 publication Critical patent/ATE500236T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
AT07710015T 2006-01-09 2007-01-09 Mit lanthionin verwandte verbindungen zur behandlung entzündlicher krankheiten ATE500236T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75725206P 2006-01-09 2006-01-09
US78179406P 2006-03-13 2006-03-13
US80414906P 2006-06-07 2006-06-07
PCT/US2007/060277 WO2007082208A2 (en) 2006-01-09 2007-01-09 Lanthionine-related compounds for the treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
ATE500236T1 true ATE500236T1 (de) 2011-03-15

Family

ID=38051848

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07710015T ATE500236T1 (de) 2006-01-09 2007-01-09 Mit lanthionin verwandte verbindungen zur behandlung entzündlicher krankheiten

Country Status (10)

Country Link
US (1) US7683055B2 (de)
EP (1) EP1981862B1 (de)
JP (1) JP5367377B2 (de)
AT (1) ATE500236T1 (de)
AU (1) AU2007204757B2 (de)
CA (1) CA2636042C (de)
DE (1) DE602007012833D1 (de)
DK (1) DK1981862T3 (de)
PT (1) PT1981862E (de)
WO (1) WO2007082208A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305834A1 (de) * 2009-10-02 2011-04-06 Advanced Practical Diagnostics N.V. Haplotyp des KATIII-Gens
MY160825A (en) * 2009-12-28 2017-03-31 Ajinomoto Kk Lanthionine derivatives
EP2567225B1 (de) 2010-05-04 2019-10-02 Virginia Tech Intellectual Properties, Inc. Der lanthionin-synthetase-komponente c ähnliche proteine als molekulare targets zur verhinderung und behandlung von erkrankungen und störungen
WO2012027455A1 (en) * 2010-08-24 2012-03-01 The University Of Toledo Glutathione-lanthionine compounds and methods related thereto
CN102670796A (zh) * 2012-05-22 2012-09-19 广西天天乐药业股份有限公司 一种治疗脾胃虚弱的中药及其制备方法
US11084836B2 (en) * 2016-02-26 2021-08-10 The University Of Toledo Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same
WO2018156429A1 (en) * 2017-02-23 2018-08-30 The University Of Toledo Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2283186A (en) * 1942-05-19 Thiazane-j
US6025395A (en) * 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US20030166554A1 (en) * 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US20030185754A1 (en) * 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
WO2002066672A2 (en) * 2001-01-16 2002-08-29 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists

Also Published As

Publication number Publication date
EP1981862B1 (de) 2011-03-02
US20070197515A1 (en) 2007-08-23
DE602007012833D1 (de) 2011-04-14
JP5367377B2 (ja) 2013-12-11
AU2007204757B2 (en) 2012-09-06
CA2636042C (en) 2014-10-14
WO2007082208A3 (en) 2007-09-13
US7683055B2 (en) 2010-03-23
CA2636042A1 (en) 2007-07-19
WO2007082208A2 (en) 2007-07-19
JP2009522377A (ja) 2009-06-11
DK1981862T3 (da) 2011-06-14
AU2007204757A1 (en) 2007-07-19
PT1981862E (pt) 2011-06-01
EP1981862A2 (de) 2008-10-22

Similar Documents

Publication Publication Date Title
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
PH12015501964B1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
DE602007006010D1 (de) Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
DE602007012133D1 (de) Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
TW200612892A (en) Novel compounds
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
IN2012DN00971A (de)
WO2014047427A3 (en) Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
TW200745003A (en) Novel compounds
WO2007068894A3 (en) Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
EA201001639A1 (ru) Композиции и способы их получения и применения
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
ATE500236T1 (de) Mit lanthionin verwandte verbindungen zur behandlung entzündlicher krankheiten
WO2007066336A3 (en) Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
UA111210C2 (uk) Антибактеріальні 3,4-дигідро-1h-[1,8]нафтиридинони, заміщені циклопента[c]піролом
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
UA107183C2 (uk) Феніламіно-ізонікотинамідні сполуки, їх застосування, фармацевтична композиція, що їх містить, та спосіб лікування гіперпроліферативних захворювань
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
EP2528440A4 (de) Substituierte norinden-isochinoline, synthese davon und verfahren zu ihrer verwendung
SMT201300112B (it) Sale citrato di 9E-15-(2-pirrolidin-1-il-etossi)-7,12,25-triossa-19,21,24-triaza-tetracicloÄ18.3.1.1(2,5).1(14,18)Üesacos a-1(24),2,4,9,14,16,18(26),20,22-nonaene

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1981862

Country of ref document: EP